Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its ...

McKesson (NYSE: MCK) Q3 2025 Earnings Call Feb 05, 2025, 4:30 p.m. ET Please stand by. Welcome to McKesson's third quarter ...

McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on ...

Irving-based McKesson (NYSE: MCK) announced on Feb. 4 an agreement to buy an 80% controlling interest in New Providence, New ...

Shares of McKesson Corp. MCK slipped 1.63% to $594.75 Friday, on what proved to be an all-around rough trading session for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and ...

Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the conference over to Rachel ...

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

McKesson inked a deal to buy a controlling interest in Prism Vision Holdings, as it also logged higher profit and revenue in its fiscal third quarter. The drug distributor said Wednesday that it ...

Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95. We are also pleased to announce the ...

Vitalone confirmed the company raised its adjusted EPS guidance to a range of $32.55 to $32.95 for fiscal 2025, representing 19%-20% year-over-year growth. Management raised full-year guidance for ...

Healthcare distributor and services company McKesson (NYSE:MCK) in Q4 CY2024, but sales rose 17.8% year on year to $95.29 ...